Furthermore, in the setting of leukemia, a recent single-agent study of dactinomycin administered at a dose of 15 μg/kg for 5 consecutive days every 2 to 4 weeks in adults with relapsed/refractory NPM1-mutated AML demonstrated significant clinical activity, with four out of nine patients demonstrating a complete response [23]. This evidence concerns the gene NPM1 and acute myeloid leukemia.